A detailed history of Neuberger Berman Group LLC transactions in Genmab A/S stock. As of the latest transaction made, Neuberger Berman Group LLC holds 48,120 shares of GMAB stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,120
Previous 50,218 4.18%
Holding current value
$1.17 Million
Previous $1.5 Million 19.51%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$25.13 - $30.27 $52,722 - $63,506
-2,098 Reduced 4.18%
48,120 $1.21 Million
Q1 2024

May 13, 2024

BUY
$26.43 - $32.77 $1.33 Million - $1.65 Million
50,218 New
50,218 $1.5 Million
Q4 2023

Feb 09, 2024

SELL
$27.94 - $35.44 $141,571 - $179,574
-5,067 Reduced 11.47%
39,095 $1.24 Million
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $1.56 Million - $1.87 Million
44,162 New
44,162 $1.56 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $16B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.